Search
Research
SCN1A Variants in vaccine-related febrile seizures: A prospective studyPathogenic SCN1A variants may be identified in infants with vaccine-proximate febrile seizures
Latest news & events at the Wesfarmers Centre of Vaccines & Infectious Diseases.
Research
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the Costa Rica Vaccine and PATRICIA trialsThe main aim of the study was to ascertain HPV-16/18 vaccine efficacy in both full and naive cohorts and to explore protection conferred against non-vaccine HPV
Research
The effectiveness of influenza vaccination in preventing hospitalisation in children in Western AustraliaThis study aimed to determine the vaccine effectiveness of the southern hemisphere trivalent inactivated influenza vaccine (TIV) in preventing...
Research
Streptococcus pneumoniae and Haemophilus influenzae in paediatric meningitis patients at Goroka General HospitalThis research presents serotype, antimicrobial susceptibility and outcome data from paediatric meningitis patients prior to introduction of Haemophilus...
Research
A prospective cohort study comparing the reactogenicity of trivalent influenza vaccine in pregnant and non-pregnant women.Influenza vaccination during pregnancy can prevent serious illness in expectant mothers and provide protection to newborns...
Research
Human infant memory B cell and CD4+ T cell responses to HibMenCY-TT glyco- conjugate vaccineCarrier-specific T cell and polysaccharide-specific B cell memory responses are not well characterised in infants following glyco-conjugate vaccination.
Research
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in childrenOur study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB, CSLD and bronchiectasis.
Research
Boosting the influenza vaccine schedule in children with cancer: a prospective open-label studyCurrent immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.
Research
Immunogenicity and Safety of a 2 + 1 DTPa Priming Schedule in Australian Infants and the Impact of Maternally Derived Antibodies on Pertussis Antibody Responses up to 4 Years of AgeWe assessed the impact of maternally derived pertussis antibodies on infant responses to a 2 + 1 vaccine schedule (6 weeks, 12 weeks, and 12 months). Infants with baseline antibodies showed lower IgG responses following the primary vaccination series, but this did not impair booster responses at 4 years of age.